Literature DB >> 22670089

The tip of the iceberg: a countercurrents series.

S A Narod.   

Abstract

Year:  2012        PMID: 22670089      PMCID: PMC3364760          DOI: 10.3747/co.19.1103

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  7 in total

Review 1.  Testing for CHEK2 in the cancer genetics clinic: ready for prime time?

Authors:  S A Narod
Journal:  Clin Genet       Date:  2010-07       Impact factor: 4.438

2.  Germline mutations in HOXB13 and prostate-cancer risk.

Authors:  Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

3.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Authors:  Ella R Thompson; Samantha E Boyle; Julie Johnson; Georgina L Ryland; Sarah Sawyer; David Y H Choong; Georgia Chenevix-Trench; Alison H Trainer; Geoffrey J Lindeman; Gillian Mitchell; Paul A James; Ian G Campbell
Journal:  Hum Mutat       Date:  2011-11-04       Impact factor: 4.878

4.  Mutations of the MYH gene do not substantially contribute to the risk of breast cancer.

Authors:  Mario E Beiner; William W Zhang; Shiyu Zhang; Steven Gallinger; Ping Sun; Steven A Narod
Journal:  Breast Cancer Res Treat       Date:  2008-05-04       Impact factor: 4.872

5.  Germline 657del5 mutation in the NBS1 gene in breast cancer patients.

Authors:  Bohdan Górski; Tadeusz Debniak; Bartlomiej Masojć; Marek Mierzejewski; Krzysztof Medrek; Cezary Cybulski; Anna Jakubowska; Grzegorz Kurzawski; Maria Chosia; Rodney Scott; Jan Lubiński
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

6.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

7.  Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.

Authors:  K A Schrader; S Masciari; N Boyd; C Salamanca; J Senz; D N Saunders; E Yorida; S Maines-Bandiera; P Kaurah; N Tung; M E Robson; P D Ryan; O I Olopade; S M Domchek; J Ford; C Isaacs; P Brown; J Balmana; A R Razzak; P Miron; K Coffey; M B Terry; E M John; I L Andrulis; J A Knight; F P O'Malley; M Daly; P Bender; R Moore; M C Southey; J L Hopper; J E Garber; D G Huntsman
Journal:  J Med Genet       Date:  2010-10-04       Impact factor: 6.318

  7 in total
  2 in total

Review 1.  Cancer genetics, precision prevention and a call to action.

Authors:  Clare Turnbull; Amit Sud; Richard S Houlston
Journal:  Nat Genet       Date:  2018-08-29       Impact factor: 38.330

2.  Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.

Authors:  Patricia Ashton-Prolla; Fernando Regla Vargas
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.